Sökning: WFRF:(Fransson Göran) > Cost-effectiveness ...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 03727naa a2200373 4500 | |
001 | oai:DiVA.org:liu-45524 | |
003 | SwePub | |
008 | 091011s2005 | |||||||||||000 ||eng| | |
009 | oai:prod.swepub.kib.ki.se:1929637 | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-455242 URI |
024 | 7 | a https://doi.org/10.1016/j.ahj.2004.07.0202 DOI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:19296372 URI |
040 | a (SwePub)liud (SwePub)ki | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a for2 swepub-publicationtype |
100 | 1 | a Aspelin, P.u Karolinska Institutet4 aut |
245 | 1 0 | a Cost-effectiveness of iodixanol in patients at high risk of contrast-induced nephropathy |
264 | 1 | b Elsevier BV,c 2005 |
338 | a print2 rdacarrier | |
520 | a Background: Acute renal failure after contrast-induced nephropathy is a clinically important and costly complication after the use of iodine-based contrast media. We investigated the cost and cost-effectiveness of 2 contrast media in patients at high risk of contrast-induced nephropathy. Methods: The analyses were based on a randomized, prospective, multinational clinical study comparing the nephrotoxic effects of an isosmolar nonionic contrast medium, iodixanol, with those of a low-osmolar nonionic contrast medium, iohexol. Resource utilization data were obtained from the study and from a retrospective review of patients' hospital records. Swedish, German, and French unit prices were applied to resources used. Between-group differences in average costs were analyzed using a nonparametric bootstrap method. Results: Resource utilization data for 125 patients were analyzed. Seven contrast media-related serious adverse reactions, of which 6 were acute renal failures, were noted in 6 patients receiving iohexol. Two patients in the iodixanol group had 1 nonserious reaction each. The mean hospitalization cost per patient was €489, €573, and €393 lower after iodixanol than after iohexol using Swedish, German, and French unit prices, respectively. The mean per-patient costs of treating adverse drug reactions were €371, €399, and €445 lower after iodixanol than after iohexol, using the respective unit prices (P = 0.01). Iodixanol was cost-effective compared with iohexol, with both lower costs and better effects related to fewer adverse drug reactions. Conclusions: The isosmolar contrast medium iodixanol appears to be cost-effective when compared with a low-osmolar contrast medium, iohexol, in diabetic patients with renal impairment undergoing angiography. © 2005, Elsevier Inc. All rights reserved. | |
653 | a MEDICINE | |
653 | a MEDICIN | |
700 | 1 | a Aubry, P.u Department of Cardiology, Ctr. Hosp. Universitaire Bichat, Paris, France4 aut |
700 | 1 | a Fransson, Sven Göranu Östergötlands Läns Landsting,Linköpings universitet,Hälsouniversitetet,Institutionen för medicin och vård,Kardiologiska kliniken4 aut0 (Swepub:liu)svefr70 |
700 | 1 | a Strasser, R.u Department of Cardiology, Heart Center, University of Technology, Dresden, Germany4 aut |
700 | 1 | a Willenbrock, R.u Department of Cardiology, Hospital St. Elisabeth, Halle, Germany4 aut |
700 | 1 | a Lundkvist, J.u Karolinska Institutet4 aut |
710 | 2 | a Karolinska Institutetb Department of Cardiology, Ctr. Hosp. Universitaire Bichat, Paris, France4 org |
773 | 0 | t American Heart Journald : Elsevier BVg 149:2, s. 298-303q 149:2<298-303x 0002-8703x 1097-6744 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-45524 |
856 | 4 8 | u https://doi.org/10.1016/j.ahj.2004.07.020 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:1929637 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.